Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
出版年份 2019 全文链接
标题
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
作者
关键词
-
出版物
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 50, Issue 2, Pages 193-203
出版商
Wiley
发表日期
2019-06-27
DOI
10.1111/apt.15316
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances
- (2018) Mazen Noureddin et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease
- (2018) Shan Li et al. BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
- (2017) Hannes Hagström et al. JOURNAL OF HEPATOLOGY
- Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option
- (2017) Gauri Dhir et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH
- (2017) Eduardo Vilar-Gomez et al. LIVER INTERNATIONAL
- High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men
- (2017) Jieun Lee et al. PLoS One
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
- (2016) Stuart McPherson et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
- (2016) Joel T. Haas et al. Annual Review of Physiology
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort
- (2016) Veronica Wendy Setiawan et al. HEPATOLOGY
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis
- (2016) Khalidur Rahman et al. LABORATORY INVESTIGATION
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
- (2016) Young-Sun Lee et al. MEDIATORS OF INFLAMMATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
- (2015) Robert J. Wong et al. GASTROENTEROLOGY
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
- (2015) Mattias Ekstedt et al. HEPATOLOGY
- High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
- (2015) Paola Portillo-Sanchez et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis
- (2013) J. H. Hoofnagle et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression
- (2013) M. Katout et al. AMERICAN JOURNAL OF HYPERTENSION
- Extrahepatic complications of nonalcoholic fatty liver disease
- (2013) Matthew J. Armstrong et al. HEPATOLOGY
- The global NAFLD epidemic
- (2013) Rohit Loomba et al. Nature Reviews Gastroenterology & Hepatology
- Association between metabolic syndrome and the development of non-alcoholic fatty liver disease
- (2013) YI WANG et al. Experimental and Therapeutic Medicine
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States
- (2012) Donghee Kim et al. HEPATOLOGY
- C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice
- (2012) Jinmi Lee et al. PLoS One
- C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients
- (2011) Esther Zimmermann et al. JOURNAL OF HEPATOLOGY
- Epidemiology of Non-Alcoholic Fatty Liver Disease
- (2010) Stefano Bellentani et al. DIGESTIVE DISEASES
- Harmonizing the Metabolic Syndrome
- (2009) K.G.M.M. Alberti et al. CIRCULATION
- High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population
- (2009) Tomomi Kogiso et al. JOURNAL OF GASTROENTEROLOGY
- Pathogenesis of non-alcoholic fatty liver disease
- (2009) J. K. Dowman et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More